#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Liver transplant rejection Choroid melanoma Cervix carcinoma recurrent Adenovirus infection Marfan's syndrome Hidradenitis Neuroblastoma recurrent Glomerulonephritis Piriformis syndrome Desmoid tumour HER2 gene amplification Paget's disease of the vulva Candida infection Meningococcal immunisation Conjunctivitis allergic More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis – Basic Information Mucopolysaccharidosis Pituitary-dependent Cushing’s syndrome – Trials in Disease Hereditary hypophosphataemic rickets – Treatment Acute respiratory distress syndrome – Diagnostics Sarcoma – Trials in Disease Mast cell activation syndrome – Trials in Disease Idiopathic pulmonary fibrosis – Diagnostics Chordoma – Life with Disease Systemic sclerosis pulmonary – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Itepekimab Camonsertib Atrasentan Hydrochloride Rapcabtagene Autoleucel JX10 Emapalumab Anhydrous Docetaxel Abt-494 Vismodegib Calcium Pantothenate Bp Zidesamtinib ULTEVURSEN METAMIZOLE SODIUM Roxadustat APROTININ Ro7790121 Technetium (99Mtc) Lutropin Alfa Cendakimab Dornase Alfa More therapies…

    Learn about Your Condition

    Myositis Inguinal hernia Meningococcal infection Palmoplantar pustulosis Oesophageal disorder Laryngeal cancer stage II Penile cancer Thalassaemia beta Catatonia Colon cancer Immune thrombocytopenia Transplant rejection Pericarditis Gouty arthritis Urinary tract infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Migraine

  • A study to evaluate the effect of rimegepant in patients with migraine and obesity

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Rimegepant
    Austria

  • A Study Testing Cabergoline to Prevent and Treat Episodic Migraine in Patients with Recurring Migraine Headaches

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Cabergoline
    Denmark

  • Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    Austria Czechia Denmark France Germany Italy +3

  • Study on Eptinezumab for Migraine: Understanding How It Works and Finding Patient Response Markers for Migraine Sufferers

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Eptinezumab
    Italy

  • Study on the Safety and Effectiveness of Atogepant for Preventing Chronic Migraine in Children Aged 12 to 17

    Recruiting

    3 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Atogepant
    Denmark Hungary Italy The Netherlands Poland Portugal

  • Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Botulinum Toxin Type A
    • Erenumab
    • Fremanezumab
    Norway
1 2 3 … 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!